AMARIN CORP PLC\UK Repayments of Long-Term Debt
AMARIN CORP PLC\UK (AMRN) reported Repayments of Long-Term Debt of $50.34 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2023-03-01
- AMARIN CORP PLC\UK repayments of long-term debt for the quarter ending 2020-12-31 was $9.42M, a 7.75% decline year-over-year.
- AMARIN CORP PLC\UK repayments of long-term debt for the quarter ending 2020-09-30 was $12.99M, a 45.84% increase year-over-year.
- AMARIN CORP PLC\UK repayments of long-term debt for the quarter ending 2020-06-30 was $14.60M, a 23.01% decline year-over-year.
- AMARIN CORP PLC\UK repayments of long-term debt for the quarter ending 2020-03-31 was $13.33M.
- AMARIN CORP PLC\UK repayments of long-term debt for fiscal 2020 was $50.34M, a 59.03% increase from fiscal 2019.
- AMARIN CORP PLC\UK repayments of long-term debt for fiscal 2019 was $31.65M, a 115.47% increase from fiscal 2018.
- AMARIN CORP PLC\UK repayments of long-term debt for fiscal 2018 was $14.69M, a 342.20% increase from fiscal 2017.
- AMARIN CORP PLC\UK repayments of long-term debt for fiscal 2017 was $3.32M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 3 month as first filed | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $9.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $22.41M derived: sum of 2 quarters · filed 2023-03-01 | $37.01M derived: sum of 3 quarters · filed 2023-03-01 | $50.34M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $12.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $27.59M derived: sum of 2 quarters · filed 2021-11-03 | $40.92M 10-Q · filed 2021-11-03 | $51.13M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $14.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $27.93M 10-Q · filed 2021-08-05 | $38.14M derived: sum of 3 quarters · filed 2022-03-01 | $47.04M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $13.33M 10-Q · filed 2021-04-29 | -$13.33M 10-Q · filed 2020-04-30 | $23.54M derived: sum of 2 quarters · filed 2022-03-01 | $32.45M derived: sum of 3 quarters · filed 2022-03-01 | $51.41M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $10.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $19.12M derived: sum of 2 quarters · filed 2022-03-01 | $38.08M derived: sum of 3 quarters · filed 2022-03-01 | $31.65M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $8.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $27.86M derived: sum of 2 quarters · filed 2020-11-05 | $21.44M 10-Q · filed 2020-11-05 | $25.59M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $18.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $12.53M 10-Q · filed 2020-08-04 | $16.68M derived: sum of 3 quarters · filed 2021-02-25 | $20.51M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$6.42M 10-Q · filed 2020-04-30 | $6.42M 10-Q · filed 2019-05-01 | -$2.27M derived: sum of 2 quarters · filed 2021-02-25 | $1.55M derived: sum of 3 quarters · filed 2021-02-25 | $4.48M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $4.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $7.98M derived: sum of 2 quarters · filed 2021-02-25 | $10.90M derived: sum of 3 quarters · filed 2021-02-25 | $14.69M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $3.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $6.75M derived: sum of 2 quarters · filed 2019-11-05 | $10.54M 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $2.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $6.71M 10-Q · filed 2019-07-31 | |||
| 2018-03-31 | $3.79M 10-Q · filed 2019-05-01 | ||||
| 2017-12-31 | $3.32M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |